文献速递银屑病与炎症性皮肤病

依奇珠单抗治疗银屑病7项临床试验的短期与长期安全性结局:依那西普对照与整合数据

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
PubMed 文献 · J Am Acad Dermatol · 2016-11-23

该研究整合7项临床试验数据,评估依奇珠单抗治疗银屑病的安全性,共4209例患者接受依奇珠单抗,总暴露6480患者年。诱导期依奇珠单抗与依那西普的治疗中出现不良事件发生率分别为251和236/100患者年,严重不良事件均为8.3/100患者年;维持期依奇珠单抗的治疗中出现不良事件和严重不良事件发生率分别为100.4和7.8/100患者年。结论认为依奇珠单抗安全性可接受,维持期未见意外安全性发现。

要点

  • 依奇珠单抗治疗银屑病总暴露6480患者年,安全性总体可接受。
  • 诱导期依奇珠单抗与依那西普不良事件发生率分别为251和236/100患者年。
  • 维持期依奇珠单抗严重不良事件发生率为7.8/100患者年。

核心结论

  • 依奇珠单抗在银屑病维持治疗中安全性可接受,未见意外安全性发现。
  • 仍需更多长期数据。

研究设计与样本

  • 整合7项临床试验的安全性数据,包括12周诱导期、12至60周维持期及全部依奇珠单抗治疗患者。
  • 共4209例患者接受依奇珠单抗,总暴露6480患者年,报告每100患者年的暴露调整发生率。

主要发现

  • 诱导期依奇珠单抗与依那西普的治疗中出现不良事件发生率分别为251和236/100患者年。
  • 诱导期两组严重不良事件发生率均为8.3/100患者年。
  • 维持期依奇珠单抗的治疗中出现不良事件和严重不良事件发生率分别为100.4和7.8/100患者年。
  • 全部7项试验依奇珠单抗治疗患者中念珠菌感染发生率为2.5/100患者年。
  • 诱导期依奇珠单抗与依那西普的特别关注治疗中出现不良事件(包括严重感染、恶性肿瘤、主要心血管不良事件)发生率相当。

临床怎么用

  • 临床使用依奇珠单抗治疗银屑病时,可参考其短期和长期安全性数据评估风险。
  • 诱导期特别关注不良事件发生率与依那西普相当,维持期严重不良事件发生率较低。

局限性

  • 需要更多长期数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety of biologics is important when treating patients with psoriasis. OBJECTIVE: We sought to determine the safety of ixekizumab in psoriasis. METHODS: Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported. RESULTS: Overall, 4209 patients received ixekizumab (total exposure: 6480 patient-years). During the induction period, the IRs of patients experiencing 1 or more treatment-emergent adverse event (AE) were 251 and 236 among ixekizumab- and etanercept-treated patients, respectively, and for serious AEs was 8.3 in both groups. During maintenance, for ixekizumab, the IRs of treatment-emergent AEs and serious AEs were 100.4 and 7.8, respectively. Among all ixekizumab-treated patients from 7 trials, the IR of Candida infections was 2.5. The IRs of treatment-emergent AEs of special interest (including serious infections, malignancies, major adverse cardiovascular events) were comparable for ixekizumab and etanercept during the induction period. LIMITATIONS: Additional long-term data are required. CONCLUSION: Ixekizumab had an acceptable safety profile with no unexpected safety findings during ixekizumab maintenance in psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2016. PMID: 27889292. doi:10.1016/j.jaad.2016.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。